Elsevier Brings Latest Book Title, ChemApps: Strategic Applications of Named Reactions in Organic Synthesis (SANROS), to the App Store

App for iPhone and iPod touch provides researchers, students and practicing chemists with trusted data and unique search and filter functions

Waltham, MA, April 26, 2012 – Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the release of ChemApps: Strategic Applications of Named Reactions in Organic Synthesis (SANROS), the second in a new series of apps for iPhone, iPod touch, or iPad based on Elsevier books. The first title, NeuroApps: MRI Atlas of Human White Matter, is also available on the App Store.

Created from the best-selling Strategic Applications of Named Reactions in Organic Synthesis by László Kürti and Barbara Czakó, ChemApps: SANROS provides organic chemists with time-saving information about chemical reactions from a trusted source, along with unique search and filter functions.

“We’re honored to adapt Kürti’s and Czakó’s indispensable print reference for the iPhone and iPod touch,” said Suzanne BeDell, Managing Director, Science and Technology Books, Elsevier. “With this new app, busy researchers, students and practicing chemists will be able to effortlessly solve a problem on the go – in the lab or in the field – when the full reference book isn’t at hand.” 

ChemApps: SANROS, available exclusively on the App Store, enables professional organic chemists to search and examine the chemical transformations extracted from the book using new interactive features:

“ChemApps: SANROS is ideal for professionals in the field or those learning named processes as part of an undergraduate or graduate course,” said Laura Colantoni, Vice President of Science Publishing and Marketing for S&T Books, Elsevier.

The ChemApps: SANROS App is available for $9.99 from the App Store on iPhone and iPod touch or at www.itunes.com/appstore. A free version, featuring 25 named reactions, is also available to download.

To watch the video trailer, please visit: http://www.youtube.com/watch?v=rqAcDeQULrU&feature=youtu.be

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Dan O'Connell
Elsevier Science & Technology Books
+1 781 663 5284
d.oconnell@elsevier.com